Skip to content
Peptigraph home

SYNCHRONIZE™-2: Survodutide Phase 3 trial (NCT06066528)

A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
755
actual
Start
27 Nov 2023 (actual)
Primary completion
12 Dec 2025 (actual)
Sponsor
Boehringer Ingelheim
Design

Arms and doses

NCT06066528 study arms
ArmTypeInterventionsDescription
Survodutide 3.6 mgExperimentalCombination Product: SurvodutideNot stated
Survodutide 6.0 mgExperimentalCombination Product: SurvodutideNot stated
PlaceboPlacebo comparatorCombination Product: PlaceboNot stated
Endpoints

Primary endpoint

NCT06066528 primary outcomes
MeasureTime frame
Percentage change in body weight from baseline to Week 76Baseline and at Week 76
Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76Baseline and at Week 76
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT06066528 secondary outcomes
MeasureTime frame
Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 76Baseline and at Week 76
Achievement of body weight reduction ≥15% (yes/no) from baseline to Week 76Baseline and at Week 76
Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 76Baseline and at Week 76
Absolute change from baseline to Week 76 in body weight (kg)Baseline and at Week 76
Absolute change from baseline to Week 76 in glycosylated haemoglobin A1c (HbA1c) (%)Baseline and at Week 76
Absolute change from baseline to Week 76 in waist circumference (cm)Baseline and at Week 76
Absolute change from baseline to Week 76 in systolic blood pressure (SBP) (mmHg)Baseline and at Week 76
Absolute change from baseline to Week 76 in "Capacity to Resist" domain score of Eating Behaviour patient reported outcome (PRO)Baseline and at Week 76
Key secondary endpoint: Absolute change from baseline to Week 76 in Eating Behaviour PRO total scoreBaseline and at Week 76
Absolute change from baseline to Week 76 in body mass index (BMI) (kg/m2)Baseline and at Week 76
Absolute change from baseline to Week 76 in HbA1c (mmol/mol)Baseline and at Week 76
Absolute change from baseline to Week 76 in diastolic blood pressure (DBP) (mmHg)Baseline and at Week 76
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

SYNCHRONIZE-2 in obesity with type 2 diabetes

Adults with type 2 diabetes and a BMI of 27 or more were randomised 1:1:1 to weekly survodutide 3.6 mg, 6.0 mg or placebo.[2]

Mean weight change at week 76 was -8.2% on 3.6 mg, -9.8% on 6.0 mg and -3.9% on placebo.[2]

HbA1c changed by -0.9, -0.8 and -0.2 percentage points from a baseline of 7.4%.[2]

Gastrointestinal events occurred in 72.8%, 77.7% and 38.6% of the three groups.[2]

Sources

  1. 1A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes MellitusClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2026PMID 42820639Accessed 2 Oct 2026

Found an error? Report a correction.